Suppr超能文献

英国口服皮质类固醇的使用情况。

Use of oral corticosteroids in the United Kingdom.

作者信息

van Staa T P, Leufkens H G, Abenhaim L, Begaud B, Zhang B, Cooper C

机构信息

Procter & Gamble Pharmaceuticals, Staines, UK.

出版信息

QJM. 2000 Feb;93(2):105-11. doi: 10.1093/qjmed/93.2.105.

Abstract

Administration of oral corticosteroids is associated with the development of osteoporosis and an increased risk of fractures. However, the size of the treated sub-population who would benefit from preventive therapy remains uncertain. The objective of this study was to investigate the usage pattern of oral corticosteroids in a large sample representative of the general population in England and Wales. Information was obtained from the General Practice Research Database (GPRD) which contains medical records of general practitioners. Oral corticosteroid users were patients aged 18 years or older who received one or more prescriptions for oral corticosteroids. Over 1.6 million oral corticosteroid prescriptions were issued to the cohort of 244 235 oral corticosteroid users. At any point in time, oral corticosteroids were being used by 0.9% of the total adult GPRD population. The highest use (2.5%) was by people between 70 and 79 years of age. Respiratory disease was the most frequently recorded indication for oral corticosteroid treatment (40%). Patients with arthropathies were most likely to use long-term, continuous treatment, and patients with chronic obstructive pulmonary disease least likely (19.3% and 6.1%, respectively, used oral corticosteroids for more than 2 years). The overall use of bone-active medication (oestrogens, bisphosphonates, vitamin D, and calcitonin) during oral corticosteroid treatment was low (between 4.0% and 5.5%). The current population in the UK at risk of developing corticosteroid-induced fractures might be as large as 350 000. Identification of these patients will be important for implementing preventive strategies in a cost-effective manner.

摘要

口服皮质类固醇的使用与骨质疏松症的发生以及骨折风险增加有关。然而,能从预防性治疗中获益的接受治疗亚人群的规模仍不确定。本研究的目的是调查在英格兰和威尔士具有总体人群代表性的大样本中口服皮质类固醇的使用模式。信息来自包含全科医生医疗记录的全科医疗研究数据库(GPRD)。口服皮质类固醇使用者为18岁及以上接受过一张或多张口服皮质类固醇处方的患者。向244235名口服皮质类固醇使用者队列开出了超过160万张口服皮质类固醇处方。在任何时间点,GPRD成年总人口中有0.9%的人正在使用口服皮质类固醇。使用率最高的是70至79岁的人群(2.5%)。呼吸系统疾病是口服皮质类固醇治疗最常记录的适应症(40%)。患有关节病的患者最有可能使用长期、持续治疗,而慢性阻塞性肺疾病患者最不可能(分别有19.3%和6.1%的患者使用口服皮质类固醇超过2年)。口服皮质类固醇治疗期间骨活性药物(雌激素、双膦酸盐、维生素D和降钙素)的总体使用率较低(在4.0%至5.5%之间)。英国目前有发生皮质类固醇诱导性骨折风险的人群可能多达35万。识别这些患者对于以具有成本效益方式实施预防策略将很重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验